LETTERS TO THE EDITOR
To the Editor, I read with interest the article by Vinod et al. [1] entitled "Kasabach-Merritt Syndrome in an Adult" in a recent issue of the Turkish Journal of Hematology.
Related to this article, I would like to add that Özsoylu [2] reported megadose methylprednisolone (MDMP) treatment for different hematological conditions including hemangiomas, infantile hemangiomatosis, and Kasabach-Merritt syndrome. Özsoylu [2] recommended the daily use of MDMP at 30 mg/kg for 3 days, then 20 mg/kg for 4 days and subsequently 10, 5, 2, and 1 mg/kg with each dose administered for 1 week around 6 AM as a single dose [2, 3] . Özsoylu [2] treated patients who were resistant to conventional corticosteroid treatment either orally or intravenously over the course of 10-15 min [2, 3] . Conventional corticosteroid treatment and MDMP were comparatively studied for the treatment of hemangiomas and it was observed that MDMP was superior [4] .
In our department, eight patients with infantile hemangiomas were treated with interferon-α2a plus oral prednisolone without observing severe complications. In this study, the median age was 4 months (range: 3-12 months); six of them were female and two were male. Three cases were not followed and three patients achieved complete regression while a partial regression was observed in two others. The beneficial results were obtained with interferon-α2a plus oral prednisolone treatment in these cases [5] .
On the other hand, vascular endothelial growth factor (VEGF) is recognized as an essential regulator of blood vessel growth. The use of anti-VEGF abolishes this vascular endothelial growth-promoting activity in vitro [6] . Three patients with periocular epithelioid hemangioma were treated with anti-VEGF successfully [7] . Although recent studies have indicated the effectiveness of anti-VEGF treatment in these cases, there is not a significant number of clinical trials reported. 
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Bendamustine and Rituximab

To the Editor,
We read "Early Direct Antiglobulin Test Negativity After Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases" [1] . Eren and Suyanı noted that "BR seems to be an important treatment of choice in terms of eliminating the poor prognostic factor of direct antiglobulin test (DAT) positivity and assuring safe cessation of steroid treatment due to rapid achievement of DAT negativity" [1] . The interesting observation of a negative DAT test should be discussed. There is another possibility that Eren and Suyanı did not mention. In their report, Eren and Suyanı noted that no titer was provided [1] . Whether the negative result is a false negative result should be discussed. For DAT testing, the prozone phenomenon is observable and it is important to consider this phenomenon in the interpretation of unexpected false negative DAT tests [2, 3, 4] . 
Conflict of Interest:
The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.
